Achieve Life Sciences
ACHV
31 hedge funds and large institutions have $9.97M invested in Achieve Life Sciences in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 9 closing their positions.
2,829% more call options, than puts
Call options by funds: $205K | Put options by funds: $7K
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
0.68% more ownership
Funds ownership: 20.43% → 21.11% (+0.68%)
6% less funds holding
Funds holding: 33 → 31 (-2)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
32% less capital invested
Capital invested by funds: $14.6M → $9.97M (-$4.66M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$810K |
| 2 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$798K |
| 3 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$363K |
| 4 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$132K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$112K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$924K |
| 2 |
DAM
DLD Asset Management
New York
|
-$345K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$259K |
| 4 |
PVI
Pura Vida Investments
New York
|
-$131K |
| 5 |
Two Sigma Advisers
New York
|
-$95K |
ACHV Hedge Fund Activity: Q2 2022 in Review
31 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Achieve Life Sciences (ACHV) for Q2 2022, worth a combined $9.97M — down 32% from $14.6M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ACHV and 7 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 11 added.
The largest buyer was Wells Fargo, adding an estimated $810K. The largest seller was Altium Capital Management, exiting entirely with an estimated $924K sold.
- 31 institutional investors held Achieve Life Sciences (ACHV) as of Q2 2022, down from 33 in Q1 2022.
- Funds reported $9.97M of Achieve Life Sciences stock for Q2 2022, down 32% quarter-over-quarter.
- 7 funds opened new Achieve Life Sciences positions in Q2 2022 and 9 closed out, a net change of -2 holders.
- The largest Achieve Life Sciences buyer in Q2 2022 was Wells Fargo, an estimated $810K added.
- The largest Achieve Life Sciences seller in Q2 2022 was Altium Capital Management, an estimated $924K sold.
Based on aggregated 13F filings for Q2 2022.